Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”) and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms (“CERo”) announces that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combination, the combined public company was renamed “CERo Therapeutics Holdings, Inc.”
Read the full article: Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination //
Source: https://www.businesswire.com/news/home/20240214145586/en/Phoenix-Biotech-Acquisition-Corp.-and-CERo-Therapeutics-Inc.-Announce-Close-of-Business-Combination